mouse ifn-γ/il- 2 double- color enzymatic elispot assay kit  (Cellular Technology Ltd)

Journal: BMC Cancer

Article Title: HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer

doi: 10.1186/s12885-025-13992-6

Figure Lengend Snippet: Summary of the ELISPOT assay of healthy donors. A Representative data of the ELISPOT assay for ES#2_E380Q, PIK#5_E545A, PIK#8_H1047L, and PIK#9_H1047Y, measured by IFN-γ (red spots) and IL-2 (blue spots). The numbers denote the spot count for IFN-γ (red). NC, negative control. TNTC: too numerous to count. B , C The ELISPOT profiles for DRB4*01:03 positive donors ( B ) and DP5 positive donors ( C ). The data for peptide pairs that showed penetrance ≥ 0.4 and g15 ratio > 2.0 are presented. HLA alleles of each donor are displayed on the top. Positive ELISPOT responses (IFN-γ) are highlighted in red. Numbers indicate the positive responses/total number of experiments (range of spot counts). The penetrance represents the number of positive donors/numbers of total donors (in red letters). The peptides with %Rank < 10 (NetMHCIIpan-4.1) is highlighted in yellow, and those with a g15 ratio > 2.0 (MHC-density assay) is highlighted in light blue. NA: not analyzed (shadowed in gray). TNTC: too numerous to count

Article Snippet: The ELISPOT assay was conducted using the human interferon-gamma (IFN-γ)/IL-2 double-color ELISPOT kit (Cellular Technology Limited, Cleveland, OH, USA), following the manufacturer’s instructions.

Techniques: Enzyme-linked Immunospot, Negative Control

Journal: bioRxiv

Article Title: Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoprotein

doi: 10.1101/2024.12.06.625234

Figure Lengend Snippet: (A) Nine participants immunized previously with three doses of ancestral WA1 vaccine were enrolled and followed after boosting. All participants’ blood was collected at baseline, week 1, 4, 8 and 17 following boosting. Fine needle aspirate of draining axillary lymph nodes were collected from all participants at week 8 post-boosting. ( B) Frequency of bivalent vaccine WA1 and BA.1 S + antibody responses were probed by ELISpot at week 1 corresponding to peak plasmablast response time-point. ( C) All participants’ (n = 9) plasma anti-S IgG titres were measured at week 0 and 4 against WA1 and BA.1 Spike protein. Results are from technical duplicates of one experiment. P values were determined by two-tailed Wilcoxon matched-pairs signed rank test. ( D) and (E) Representative flow cytometry plots and frequencies of S-binding germinal centre B cells ( BCL6 + CD38 int IgD lo CD19 + CD3 - ) and lymph node plasma cells (CD20 lo CD38 + IgD lo CD19 + CD3 - ) of fine needle aspirates from draining axillary lymph nodes at week 8 post boosting. Horizontal lines indicate median in frequency plots.

Article Snippet: Direct ex-vivo ELISpot assays were performed to determine the number of total, recombinant S-binding IgG- and IgA-secreting cells present in PBMC and enriched BMPC samples using IgG/IgA double-color ELISpot Kits (Cellular Technology Limited) according to the manufacturer’s instructions.

Techniques: Enzyme-linked Immunospot, Two Tailed Test, Flow Cytometry, Binding Assay